Description of the GiACTA trial (Stone et al, N. Engl. J. Med. 2017), a Phase III clinical trial of tocilizumab (Actemra) for the treatment of giant cell arteritis (GCA).
Happy 4th anniversary!
Today is the 4th anniversary of my diagnosis. It looks like my vasculitis is not going anywhere, but neither am I.
WORKSHOP: The 19th International Vasculitis and ANCA Workshop – April 7th – 10th, 2019, Philadelphia, PA USA
Announcing the 19th International Vasculitis and ANCA Workshop April 7-10 2019, Philadelphia, PA USA.
The MIRRA trial: Mepolizumab (Nucala) or placebo for the treatment of EGPA/Churg-Strauss Syndrome
Description of the MIRRA trial (Wechsler et al, N. Engl. J. Med. 2017), a Phase III clinical trial of mepolizumab (Nucala) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss Syndrome).
How do the IL-5 inhibitors Cinqair, Fasenra, and Nucala work?
How do the IL-5 inhibitors Cinqair (reslizumab), Fasenra (benralizumab), and Nucala (mepolizumab) work? How do they control eosinophils?
Tapers, treatments, and flares: My treatment course for EGPA/Churg-Strauss vasculitis (Oct 2014 – Apr 2018)
Treatment ups and downs for my EGPA/Churg-Strauss vasculitis from Oct 2014 through Apr 2018 detailing prednisone tapers, treatment modifications, and flares.
Living with #raredisease EGPA: Eosinophilic Granulomatosis with Polyangiitis
GSK educational video on living with #raredisease EGPA.
Step one: My diagnosis with EGPA/Churg-Strauss vasculitis
Getting a diagnosis is just the first step. Here's the story of my diagnosis with EGPA/Churg-Strauss vasculitis.
Managing vasculitis: A patient’s perspective
Patient webinar about diagnosis with EGPA/Churg-Strauss vasculitis, treatment, tracking symptoms, working with doctors, and strategies for managing vasculitis.